These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 9576812)

  • 1. Role of cross-linking agents in determining the biochemical and pharmacokinetic properties of Mgr6-clavin immunotoxins.
    Dosio F; Arpicco S; Adobati E; Canevari S; Brusa P; De Santis R; Parente D; Pignanelli P; Negri DR; Colnaghi MI; Cattel L
    Bioconjug Chem; 1998; 9(3):372-81. PubMed ID: 9576812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New coupling reagents for the preparation of disulfide cross-linked conjugates with increased stability.
    Arpicco S; Dosio F; Brusa P; Crosasso P; Cattel L
    Bioconjug Chem; 1997; 8(3):327-37. PubMed ID: 9177838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo.
    Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Knyba RE; Wawrzynczak EJ; Blakey DC
    Cancer Res; 1987 Nov; 47(22):5924-31. PubMed ID: 3499221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Production and characterisation of a recombinant single-chain anti ErbB2-clavin immunotoxin.
    D'Alatri L; Di Massimo AM; Anastasi AM; Pacilli A; Novelli S; Saccinto MP; De Santis R; Mele A; Parente D
    Anticancer Res; 1998; 18(5A):3369-73. PubMed ID: 9858910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.
    Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Blakey DC; Newell DR
    Cancer Res; 1988 Nov; 48(22):6396-403. PubMed ID: 3263186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin.
    Rosenblum MG; Marks JW; Cheung LH
    Cancer Chemother Pharmacol; 1999; 44(4):343-8. PubMed ID: 10447583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo antitumor activity of immunoconjugates prepared by linking 5-fluorouridine to antiadenocarcinoma monoclonal antibody.
    Brusa P; Dosio F; Coppo S; Pacchioni D; Arpicco S; Crosasso P; Cattel L
    Farmaco; 1997 Feb; 52(2):71-81. PubMed ID: 9181686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
    Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
    Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage.
    Kellogg BA; Garrett L; Kovtun Y; Lai KC; Leece B; Miller M; Payne G; Steeves R; Whiteman KR; Widdison W; Xie H; Singh R; Chari RV; Lambert JM; Lutz RJ
    Bioconjug Chem; 2011 Apr; 22(4):717-27. PubMed ID: 21425776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clavin, a type-1 ribosome-inactivating protein from Aspergillus clavatus IFO 8605. cDNA isolation, heterologous expression, biochemical and biological characterization of the recombinant protein.
    Parente D; Raucci G; Celano B; Pacilli A; Zanoni L; Canevari S; Adobati E; Colnaghi MI; Dosio F; Arpicco S; Cattel L; Mele A; De Santis R
    Eur J Biochem; 1996 Jul; 239(2):272-80. PubMed ID: 8706730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two anti-Thy 1.1-abrin A-chain immunotoxins prepared with different cross-linking agents: antitumor effects, in vivo fate, and tumor cell mutants.
    Thorpe PE; Blakey DC; Brown AN; Knowles PP; Knyba RE; Wallace PM; Watson GJ; Wawrzynczak EJ
    J Natl Cancer Inst; 1987 Nov; 79(5):1101-12. PubMed ID: 2890786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant ricin A chain conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds.
    Ramakrishnan S; Bjorn MJ; Houston LL
    Cancer Res; 1989 Feb; 49(3):613-7. PubMed ID: 2783383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural features of the antibody-A chain linkage that influence the activity and stability of ricin A chain immunotoxins.
    Cumber AJ; Westwood JH; Henry RV; Parnell GD; Coles BF; Wawrzynczak EJ
    Bioconjug Chem; 1992; 3(5):397-401. PubMed ID: 1329989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxin-targeted design for anticancer therapy. II: Preparation and biological comparison of different chemically linked gelonin-antibody conjugates.
    Delprino L; Giacomotti M; Dosio F; Brusa P; Ceruti M; Grosa G; Cattel L
    J Pharm Sci; 1993 Jul; 82(7):699-704. PubMed ID: 8360843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
    Trail PA; Willner D; Knipe J; Henderson AJ; Lasch SJ; Zoeckler ME; TrailSmith MD; Doyle TW; King HD; Casazza AM; Braslawsky GR; Brown J; Hofstead SJ; Greenfield RS; Firestone RA; Mosure K; Kadow KF; Yang MB; Hellström KE; Hellström I
    Cancer Res; 1997 Jan; 57(1):100-5. PubMed ID: 8988048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
    Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
    Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of mineral affinity of bisphosphonate-protein conjugates constructed with disulfide and thioether linkages.
    Wright JE; Gittens SA; Bansal G; Kitov PI; Sindrey D; Kucharski C; Uludağ H
    Biomaterials; 2006 Feb; 27(5):769-84. PubMed ID: 16055182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.
    Safavy A; Bonner JA; Waksal HW; Buchsbaum DJ; Gillespie GY; Khazaeli MB; Arani R; Chen DT; Carpenter M; Raisch KP
    Bioconjug Chem; 2003; 14(2):302-10. PubMed ID: 12643740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.
    Safavy A; Georg GI; Vander Velde D; Raisch KP; Safavy K; Carpenter M; Wang W; Bonner JA; Khazaeli MB; Buchsbaum DJ
    Bioconjug Chem; 2004; 15(6):1264-74. PubMed ID: 15546192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.